An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
An invention that strips cancer tumors' ability to hide from the body's immune system, and a better way to shock hearts back into their normal rhythm took top honors today at America's most prestigious collegiate inventing competition.
CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.
The diagnosis and treatments of congenital heart disease have improved so much that many babies now born with heart defects can still look forward to a long and fulfilling life. Just two generations ago, the majority of babies born with heart defects died before their first birthday, but today many of these conditions can be corrected.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Although an irregular heartbeat is a common malady in the United States, affecting an estimated 5 million people, the treatments for it are limited in scope and effectiveness.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF.
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International for the remede System, the first and only implantable device for the treatment of central sleep apnea.
For childhood cancer survivors, risk factors associated with lifestyle, particularly hypertension, dramatically increase the likelihood of developing serious heart problems as adults, according to a national study led by St. Jude Children's Research Hospital. The findings appear in the current issue of the Journal of Clinical Oncology.
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated heart disease), researchers found a nearly 40% recurrence rate and that AF in the young is accompanied by substantial symptoms.
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced it has received approval from the Food and Drug Administration (FDA) for its Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices). BIOTRONIK follows this milestone with the launch of its next generation unique technology platform Ilesto DX.
UC Davis Health System researchers have identified for the first time a biological pathway that is activated when blood sugar levels are abnormally high and causes irregular heartbeats, a condition known as cardiac arrhythmia that is linked with heart failure and sudden cardiac death.
A new study of patients who died of sudden cardiac arrest, a usually fatal condition that causes the heart to stop beating, shows the majority who qualified to receive potentially lifesaving treatment did not receive it.
Candida albicans is a double agent: In most of us, it lives peacefully, but for people whose immune systems are compromised by HIV or other severe illnesses, it is frequently deadly. Now a new study from Johns Hopkins and Harvard Medical School shows how targeting a specific fungal component might turn the fungus from a lion back into a kitten.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
An estimated 80 percent of patients who have obstructive sleep apnea (OSA) go undiagnosed, including Deanna G. McNeil, a 72-year-old nurse from Toronto. Before hip replacement surgery in 2010, Deanna completed the STOP-Bang questionnaire, created by Frances Chung, M.B.B.S., professor, Department of Anesthesia, University of Toronto, Ontario. Based on the questionnaire, Deanna was suspected to have OSA.
Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very costly. In-vivo methods give highly relevant information but are extremely low throughput allowing the analysis of only a handful of compounds.
University of Alabama at Birmingham cardiovascular physician Tom McElderry, M.D., has become the first surgeon in the United States to use the new IntellaTip MiFi™ XP catheter in a patient.
Evidence from people with heart disease strongly supports the existence of the molecular link first discovered in laboratory mice between the body's natural circadian rhythms and cardiac arrest or sudden cardiac death (SCD) - the No. 1 cause of death in heart attacks, a scientist said here today.
Parents beware. If your tots and teens get their hands on your energy drinks, they could experience seizures, heart palpitations or other problems that drive them to the hospital emergency room.
In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of Delayed Enhancement - MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.